OpGen > Investor Relations > Press Releases

Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle  
02/14/2017OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting
Data support ability to predict antibiotic susceptibility in hours instead of days GAITHERSBURG, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced preliminary data demonstrating the ability to rapidly and accurately predict bacterial antibiotic susceptibility using resistance gene profiles. The data were presented at the Advances in Genome Biology and Technology (AGBT) meeting, which is taking place from February 13-16, 2017 in Hollywood Beach, FL. These prelimi... 
 Printer Friendly Version
01/26/2017OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results
Achieves Revenue of Approximately $4.0 Million, a 27% Year Over Year Increase GAITHERSBURG, Md., Jan. 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2016, and summarized 2016 business highlights.  Total revenue for the full year ended December 31, 2016 was approximately $4.0 million, a 27% increase from the $3.2 million recorded for the full year ended December 31, 2015. Total revenue... 
 Printer Friendly Version
12/19/2016OpGen Supports Passage of Landmark 21st Century Cures Act to Expedite Development of Solutions for Bacterial Infections
GAITHERSBURG, Md., Dec. 19, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) issued the statement below following the passage of the 21st Century Cures legislation in support for advancing medical breakthroughs to meet some of the biggest healthcare challenges today. The statement can be attributed to Evan Jones, Chairman and CEO of OpGen: “The passage of this historic legislation provides important improvements in the regulatory framework for drugs, diagnostics, and information products ... 
 Printer Friendly Version
12/16/2016OpGen Provides ATM Program Update
GAITHERSBURG, Md., Dec. 16, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces that during the fourth quarter of 2016 it has issued approximately 3.6 million shares of its common stock under its previously announced “at the market offering” program, resulting in aggregate net proceeds to the Company of approximately $4.6 million.  The proceeds will be used to support the company’s research, development and manufacturing of product candidates, and for other general corporate purposes.... 
 Printer Friendly Version
11/14/2016OpGen Collaborates With Merck to Develop Novel Rapid Diagnostics and Informatics Tools to Combat Antibiotic Resistance
GAITHERSBURG, M.d., Nov. 14, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced it has entered into a research collaboration with Merck, known as MSD outside the United States and Canada, to develop new rapid diagnostics and information technology products to help combat the threat of antimicrobial resistance. The companies will collaborate to support OpGen’s development of rapid DNA tests and a genomic knowledgebase of antibiotic-resistant pathogens for predicting antibiotic s... 
 Printer Friendly Version
10/27/2016Large Integrated Health Outcomes Study Reveals Shifting Epidemiology In Drug Resistant Organisms
SALT LAKE CITY and GAITHERSBURG, Md., Oct. 27, 2016 (GLOBE NEWSWIRE) -- A first-of-its-kind study of 900,000 hospital admissions from an integrated health system has yielded insights into shifts in the epidemiology of multi-drug resistant organisms (MDROs) in the community. New research, funded by OpGen (NASDAQ:OPGN) and conducted by Intermountain Healthcare and Enterprise Analysis Corporation (EAC) found that Methicillin Resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diffic... 
 Printer Friendly Version
10/26/2016OpGen’s Infectious Disease Portfolio Highlighted at IDWeek 2016
GAITHERSBURG, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that its infectious disease portfolio will be featured in one oral presentation and 5 poster sessions at IDWeek 2016, which takes place from October 26-30 in New Orleans, LA. The oral presentation, given by Jacqueline Reuben, Senior Infectious Disease Epidemiologist, District of Columbia Department of Health, will illustrate OpGen’s Acuitas Lighthouse® MDRO Management System capabilities in a regi... 
 Printer Friendly Version
10/24/2016OpGen Reports 2016 Third Quarter Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Oct. 24, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the three and nine months ended September 30, 2016. Highlights of the third quarter and recent weeks include: Third-quarter revenues of $0.8 million, a 23% decrease over prior year Nine-month revenues of $3.0 million, a 65% increase over prior year Automated QuickFISH® Pathogen ID clinical trial ... 
 Printer Friendly Version
10/19/2016OpGen Announces Date of Third Quarter 2016 Financial Results Conference Call
GAITHERSBURG, Md., Oct. 19, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its third quarter 2016 financial results after close of market on Monday, October 24, 2016. Following the announcement, OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: 844-420-8185 International Dial-In Number: 216-562-0481 ... 
 Printer Friendly Version
09/08/2016OpGen, Inc. to Host Anti-Infectives Roundtable at the World Anti-Microbial Resistance Congress
GAITHERSBURG, Md., Sept. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled “Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions” on Thursday, September 8 at 3:05 p.m. ET. OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our In... 
 Printer Friendly Version
09/07/2016OpGen to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference.  Mr. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City. To listen to the presentatio... 
 Printer Friendly Version
08/09/2016OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Aug. 09, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the three and six months ended June 30, 2016. Highlights of the second quarter and recent weeks include: Achieved second quarter revenue of $1.2 million, 215% year over year growth Completed Intermountain Healthcare Retrospective MDRO Health Outcome Study Closed $10.4 million private placement ... 
 Printer Friendly Version
08/08/2016OpGen Announces Completion of the Intermountain Healthcare Retrospective MDRO Health Outcome Study
Study is the largest of its kind ever conducted in an integrated health system GAITHERSBURG, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an informatics and genomic analysis company, announces the completion of its multi-drug resistant organisms (MDRO) health outcomes study with Intermountain Healthcare. It was a collaboration between Intermountain Healthcare and Enterprise Analysis Corporation (EAC) in a retrospective study to explore multi-drug resistant organisms and C... 
 Printer Friendly Version
08/02/2016OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
GAITHERSBURG, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that financial results for the company’s second quarter ended June 30, 2016 will be released Tuesday, August 9, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (international) five minutes prior to the start of the call ... 
 Printer Friendly Version
06/20/2016OpGen Highlights Strong Performance of Acuitas® Resistome Test at ASM Microbe 2016
Test enables rapid and comprehensive genotyping of MDRO isolates GAITHERSBURG, Md., June 20, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today presented data that support the use of its Acuitas® Resistome Test in epidemiological studies to aid in routine evaluations for mechanisms of resistance among carbapenem resistant Enterobacteriaceae (CRE) at ASM Microbe 2016 in Boston. T... 
 Printer Friendly Version
06/02/2016OpGen to Present at the 6th Annual LD Micro Invitational Conference
GAITHERSBURG, Md. (June 2, 2016) – OpGen, Inc. (NASDAQ: OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announced today that Kevin Krenitsky, president, will present at the 6th Annual LD Micro Invitational conference on June 7, 2016 at 2:30 p.m. Pacific Time. The conference is being held from June 7- 9 at the Luxe Sunset Boulevard Hotel in Los Angeles.A webcast of the presentation will be available in the investor relations ... 
 Printer Friendly Version
05/20/2016OpGen Announces Closing of $10 Million Private Placement
GAITHERSBURG, Md., May 20, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the first closing of a private placement financing raising gross proceeds of $10.4 million.  The Company will use the net proceeds, after payment of offering expenses, to support the sales and marketing and continued research and development of the Company’s rapid diagnostic and Acuitas Lighthouse™ bio... 
 Printer Friendly Version
05/17/2016OpGen Supports New White House National Microbiome Initiative
Initiative to Foster a Needed Integrated Study of Microbiomes Across Various Ecosystems GAITHERSBURG, Md., May 17, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a leading developer of precision medicine tools to combat infectious disease in global healthcare settings, supports the new White House National Microbiome Initiative (NMI) and its more than $121 million of strategic investments from various Federal agencies into interdisciplinary and multi-ecosystem microbiome research and too... 
 Printer Friendly Version
05/12/2016OpGen Reports 2016 First Quarter Financial Results and Business Update
First quarter revenue increases 128% over prior year to $1.1 million First U.S. citywide quantification of Superbug pathogens completed in District of Columbia Announced pricing of $10.4 million private placement financing Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today reported financial and ... 
 Printer Friendly Version
05/12/2016OpGen Announces Pricing of $10 Million Private Placement
GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the pricing of a private placement of units, each unit consisting of one share of common stock and one warrant to purchase 0.75 of one share of common stock, for an aggregate issuance of 9,053,556 shares of common stock and warrants to purchase 6,790,169 shares of common stock. Each unit will be sold a... 
 Printer Friendly Version
05/10/2016OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
GAITHERSBURG, Md., May 10, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company’s first quarter ended March 31, 2016 will be released Thursday, May 12, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 4:30 p.m. E.T.  The call may be accessed by dialing (... 
 Printer Friendly Version
05/04/2016OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities
Consortium of Washington, D.C. Health Organizations and OpGen test over 1,000 patient samples for antibiotic resistant bacteria OpGen’s Acuitas® detection technology provides surveillance to put city ahead of MDROs and leads to proactive intervention protocols GAITHERSBURG, Md. and WASHINGTON, May 04, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) and the District of Columbia Hospital Association (DCHA) today announced the completion of a citywide evaluation with Washington, D.C.’s pu... 
 Printer Friendly Version
05/02/2016OpGen Appoints Harry J. D'Andrea to Board of Directors
GAITHERSBURG, Md., May 02, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the appointment of Harry J. D’Andrea to the company’s board of directors, effective April 29, 2016.  He will serve as a member of the board’s audit committee and will stand for reelection for a one-year term at the company’s annual meeting of stockholders, to be held June 22, 2016.    Mr. D’Andrea b... 
 Printer Friendly Version
04/11/2016New Study Data Show OpGen’s QuickFISH® Blood Culture Pathogen ID Tests to be Rapid and Cost-Effective, with Utility to Inform Antimicrobial Stewardship Decisions
Company to preview automated QuickFISH Digital Imager at 26th European Congress of Clinical Microbiology and Infectious Diseases GAITHERSBURG, Md., April 11, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that new study data on its QuickFISH® tests were presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held from Ap... 
 Printer Friendly Version
03/30/2016OpGen Announces 2015 Fourth Quarter and Full Year Financial Results
Fourth quarter revenue increases 18% over prior year period to $1.3 million Conference call begins at 10:00 a.m. Eastern time today GAITHERSBURG, Md., March 30, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today reported financial and operational results for the fourth quarter and year ended December 31, 2015. OpGen reported total revenue for the fourth quarter of 2015 of $1.3 m... 
 Printer Friendly Version
03/21/2016OpGen Announces New Members to its Clinical Advisory Board
Adds leaders in infectious disease, antibiotic resistance and genetic analysisGAITHERSBURG, Md., March 21, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc.(NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announced that four new members have joined its Clinical Advisory Board (CAB). Joining the board are Debra A. Goff, Pharm.D., FCCP, Dag Harmsen, M.D., Stefan Riedel, M.D. Ph.D., D(ABMM), FCAP, and... 
 Printer Friendly Version
03/16/2016OpGen, Inc. Announces Timing for 2015 Fourth Quarter and Year End Financial Results and Conference Call
GAITHERSBURG, Md., March 16, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company’s fourth quarter ended December 31, 2015 will be released Wednesday, March 30, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 10:00 a.m. E.T.  The call may be accessed by... 
 Printer Friendly Version
02/03/2016OpGen to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
GAITHERSBURG, Md., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016 at 2:45 p.m. Eastern time. The conference is being held from February 10 to 11 in New York City. To listen to the present... 
 Printer Friendly Version
01/13/2016OpGen, Inc., to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference
GAITHERSBURG, Md., Jan. 13, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that Chairman and Chief Executive Officer Evan Jones will present at the NobleCon12 - Noble Financial Capital Markets’ 12th Annual Investor Conference on January 20, 2016, at 10:30 a.m. Eastern Standard Time. The conference is being ... 
 Printer Friendly Version
12/17/2015OpGen's QuickFISH Rapid Pathogen ID Test Demonstrates Clinical Utility and Cost Effectiveness in Community Hospital’s Antimicrobial Stewardship Program
Published study documents annual savings at Winter Haven Hospital of more than $760,000 from use of the OpGen test, which resulted in a 30% reduction in patient length of stay and a 65% reduction in vancomycin use GAITHERSBURG, Md. , Dec. 17, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announce... 
 Printer Friendly Version
11/18/2015District of Columbia Hospital Association Chooses OpGen to Create Citywide Effort to Track Multidrug-Resistant Bacteria
DC’s Public Health Agencies, Healthcare Facilities to Examine Occurrence of “Superbugs” in First-of-Its-Kind Evaluation, Supported by the Centers for Disease Control & Prevention GAITHERSBURG, Md. and WASHINGTON, Nov. 18, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) and the District of Columbia Hospital Association (DCHA) today announced that Washington DC’s public health departments will oversee a comprehensive citywide evaluation, HARP-DC (Healthcare facility Antibiotic Resistance... 
 Printer Friendly Version
11/12/2015OpGen Reports Third Quarter Financial Results and Provides Business Update
Conference Call Begins at 4:30 p.m. Eastern Time Today GAITHERSBURG, Md., Nov. 12, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early commercial-stage company using molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers combat multi-drug resistant infections, today reported financial results for the three and nine months ended September 30, 2015. Highlights of the third quarter of 2015 and recent weeks include: OpGen chosen to ... 
 Printer Friendly Version
11/04/2015OpGen, Inc. Announces Timing for Third Quarter Financial Results and Conference Call
GAITHERSBURG, Md., Nov. 4, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that financial results for the company's third quarter ended September 30, 2015 will be released Thursday, November 12, 2015 following the close of market.   The management team will host a conference call discussing the company's financial results and recent developments on Thursday, November 12, 2015 at 4:30 p.m. E.T. The call ma... 
 Printer Friendly Version
10/12/2015Data Show “Super Bug” Surveillance System Based on OpGen’s Acuitas(R) Resistome Test Can Identify Potential Outbreaks in Hospitals and Improve Infection Control  
Researchers From Rush University Medical Center Present Data at IDWeek 2015 GAITHERSBURG, Md., Oct. 12, 2015 (GLOBE NEWSWIRE) --  OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas® Resistome Test were presented on October 10 as an oral abstract at IDWeek 2015 by Michael Lin, M.D., M.P.H., an infectious disease physician and assistant professor of medicine at Rush University Medical Cen... 
 Printer Friendly Version
09/22/2015OpGen to Present Data Showing Acuitas(R) Tests are Effective Tools for Investigating Transmission of "Super Bugs"
Acuitas Resistome Test and Whole Genome Sequence Analysis Showcased at American Society for Microbiology Conference on Next Generation Sequencing for Epidemiologic Investigation of Pathogens GAITHERSBURG, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Resistome Test and Acuitas Whole Genome Sequence (WGS) Analysis for multidrug-resistant organisms (MDROs) will be presented at the American Society for Microbiology's First Conference on... 
 Printer Friendly Version
08/13/2015OpGen Reports Second Quarter Financial Results and Provides Business Update
Conference Call Begins at 4:30 p.m. Eastern Time Today GAITHERSBURG, Md., Aug. 13, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three and six months ended June 30, 2015. Highlights of the second quarter of 2015 and recent weeks include: Acquisition of AdvanDx, Inc., a market leader in rapid molecular testing for microorganism identification Completion of a $6 mil... 
 Printer Friendly Version
08/05/2015OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
GAITHERSBURG, Md., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), today announced that financial results for the company's second quarter ended June 30, 2015 will be released Thursday, August 13, 2015 following the close of market. The management team will host a conference call discussing the company's financial results and recent developments on Thursday, August 13, 2015 at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (internationa... 
 Printer Friendly Version
07/14/2015OpGen Closes $6 Million Financing With Merck GHI to Expand Infectious Disease Diagnostic Testing Capabilities
David M. Rubin, Ph.D., Managing Director, Merck Global Health Innovation Fund, to Join OpGen Board of Directors GAITHERSBURG, Md., July 14, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the closing of a $6 million financing by the Merck Global Health Innovation Fund (Merck GHI). In connection with this financing, David M. Rubin, Ph.D., Managing Director of Merck GHI, has been appointed to OpGen's board of directors, effective immediately. Evan Jones, chairman and chief ... 
 Printer Friendly Version
07/14/2015OpGen to Acquire AdvanDx, Inc.
Gains Rapid Molecular Diagnostic Tests and Additional Sales Channels Conference Call to Begin at 10:00 a.m. Eastern Time Today GAITHERSBURG, Md., July 14, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), has agreed to acquire AdvanDx, Inc., a Woburn, Mass. developer of advanced molecular diagnostic products. The acquisition will be accounted for as a merger combination. The consummation of the merger provides OpGen with a family of FDA approved and CE marked rapid molecular tests for ... 
 Printer Friendly Version
07/13/2015Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
Five-Year Agreement Expands on Prior Supply Agreement SOUTH SAN FRANCISCO, Calif. and GAITHERSBURG, Md., July 13, 2015 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN) today announced an expanded relationship and new agreement that includes collaborating on the development of test kits and custom analytic instruments for identification, screening, and surveillance testing of multi-drug resistance organism (MDRO) genes of pathogens, such as bacteria, fungi and... 
 Printer Friendly Version
06/17/2015OpGen Reports First Quarter Financial Results and Provides Business Update
GAITHERSBURG, Md., June 17, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three months ended March 31, 2015. Highlights of the first quarter of 2015 and recent weeks include: Completing a $17.1 million initial public offering (IPO) of common stock and warrants Strengthening the management team by adding Kevin Krenitsky, M.D. as president and Tim Dec as chief financ... 
 Printer Friendly Version
06/11/2015OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
GAITHERSBURG, Md., June 11, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), today announced that financial results for the company's first quarter ended March 31, 2015 will be released Wednesday, June 17, 2015 following the close of market.   The management team will host a conference call discussing the company's financial results and recent developments on Wednesday, June 17, 2015 at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (internation... 
Download PDFPrinter Friendly Version
06/02/2015OpGen Releases Next-Generation Molecular Testing and Bioinformatics Solution for Combating Multi-Drug Resistant Infections
- Company Participating in Today's White House Forum on Antibiotic Stewardship - Acuitas® Resistome, Acuitas Whole Genome Sequencing, and Acuitas Lighthouse™ MDRO Management System Now Available GAITHERSBURG, Md., June 2, 2015 (GLOBE NEWSWIRE) --  OpGen, Inc. (Nasdaq:OPGN), an early commercial-stage molecular testing and bioinformatics company, today launched its expanded, comprehensive molecular testing and bioinformatics program for detecting and managing Gram negative multi-drug res... 
Download PDFPrinter Friendly Version
05/27/2015OpGen's Acuitas(R) MDRO Gene Tests and Bioinformatics Data to be Presented at ASM2015
Posters and Presentations Highlight Performance of OpGen's Acuitas MDRO Products GAITHERSBURG, Md., May 27, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), an early commercial stage molecular testing and bioinformatics company, today announced that new study data on its Acuitas® MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Lighthouse™ MDRO Management System will be presented at the 115th General Meeting of the American Society of Microbiology, to be held from May 30 to June 2 in New O... 
Download PDFPrinter Friendly Version
05/05/2015OpGen Announces Pricing of Initial Public Offering
GAITHERSBURG, Md., May 5, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of its initial public offering of 2,850,000 units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at a combined price to the public of $6.00 per unit. All of the units are being offered by OpGen. OpGen's common stock and warrants have been approved for listing on the NASDAQ Capital Market. The units will immediately and automaticall... 
Download PDFPrinter Friendly Version
04/29/2015OpGen’s Acuitas® MDRO Gene Test Data Presented at 25th European Congress of Clinical Microbiology and Infectious Diseases
Results from the University of Maryland School of Medicine Demonstrate Acuitas MDRO Gene Test is a Highly Sensitive and Efficient Method for Detecting the Presence of Antibiotic Resistance Genes GAITHERSBURG, Md. (April 29, 2015) – OpGen, Inc., a molecular testing and bioinformatics company, today announced that new study data on its Acuitas® MDRO Gene Test was presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held from April 25th to 28th in Co... 
Download PDFPrinter Friendly Version
04/20/2015OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer
Expands executive team to support the rollout of antibiotic-resistant infection testing and bioinformatics platform, and to help ensure public company financial controls GAITHERSBURG, Md. (April 20, 2015) – OpGen, Inc., a molecular testing and bioinformatics company, today announced the expansion of its executive management team with the appointments of former Foundation Medicine (NASDAQ: FMI) executive Kevin Krenitsky, M.D. as president, and Timothy C. Dec as interim chief financial officer.... 
Download PDFPrinter Friendly Version
03/03/2015OpGen Files Registration Statement for Proposed Initial Public Offering
GAITHERSBURG, Md. (March 3, 2015)–OpGen, Inc. today announces the filing of its registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to its proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. OpGen is in the process of applying to list its common stock under the symbol “OPGN” on The NASDAQ Capital Market.Maxim Group LLC is acting as sole book-running man... 
Download PDFPrinter Friendly Version
10/20/2014Hitachi High-Technologies Corporation and OpGen Announce Early Access Program for Human Chromosome Mapping Analytical Service
Companies to Introduce Human Chromosome ExplorerSM Cloud-Based Informatics and Data Management PlatformTokyo and Gaithersburg, Md.—October 19, 2014—Hitachi High-Technologies Corporation and OpGen, Inc., a leading genetic analysis company, today announced the introduction of an Early Access Program for its upcoming Human Chromosome ExplorerSM, human chromosome mapping analytical service for clinical research and life science research applications.The companies entered a development agreement in O... 
Download PDFPrinter Friendly Version
05/15/2014OpGen Launches First “Superbug” Molecular Screening Test to Identify Seven Critical Antibiotic Resistant Genes
OpGen Contact: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comMedia Contact: Lisa Guiterman (301) 217-9353 office lisa.guiterman@gmail.comTest Quickly Determines Colonization Risk of Multi-drug Resistant Microbes with Greater Accuracy than Currently Available OptionsGaithersburg, MD—May 15, 2014—OpGen, Inc., a Gaithersburg based molecular diagnostics company, announced today that it has launched a new molecular-based test that can quickly and reliably identify p... 
Download PDFPrinter Friendly Version
10/16/2013OpGen and Hitachi High-Technologies Corporation Enter into an Agreement to Develop Human Chromosome Mapping Service
OpGen Contacts: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comDan Budwick (Media) Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com Companies to Develop Offering that Combines Whole Genome Mapping™ with Cloud-Based Informatics and Data Management PlatformsGaithersburg, Md. and Tokyo—October 16, 2013— OpGen, Inc., a leading genetic analysis company, and Hitachi High-Technologies Corporation today announced an agreement to develop a compre... 
Download PDFPrinter Friendly Version
07/23/2013OpGen Opens CLIA Certified Clinical Services Laboratory and Launches Microbial Genetic Tests for Healthcare Associated Infections - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
OpGen Contacts: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comSusan Heins (Media) Pure Communications, Inc. (864) 286-9597 Company Expands to Address Rising Incidence of HAIs with Next Generation Diagnostic and Epidemiologic SolutionsGaithersburg, Md.—July 23, 2013— OpGen, Inc., a leading genetic analysis company, today announced that it received Clinical Laboratory Improvement Amendments (CLIA) certification and has launched a clinical services laboratory wit... 
Download PDFPrinter Friendly Version
06/03/2013OpGen Announces Partnership with Applied Maths to Provide Bioinformatics Analysis Software for Whole Genome Mapping
OpGen Contacts: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comDan Budwick (Media) Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md.—June 3, 2013— OpGen, Inc., today announced the company has entered into a strategic collaboration with Applied Maths NV, the market leader in bioinformatics and analytical solutions for public health and research laboratories, to provide advanced software tools for microbial genomics and molecular strain typing. Under the a... 
Download PDFPrinter Friendly Version
05/16/2013OpGen to Present New Data on the Application of Whole Genome Mapping in Microbial Outbreaks at the American Society for Microbiology 113th General Meeting - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
OpGen Contacts: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comKristie Wallis (Media) Pure Communications, Inc. (646) 320-3845Gaithersburg, Md.—May 16, 2013— OpGen, Inc. today announced that new data on the utility and application of its Whole Genome Mapping™ technology in the public health and health care settings will be highlighted at a company-sponsored symposium and poster presentation during the American Society for Microbiology (ASM) 113th General Meeting.... 
Download PDFPrinter Friendly Version
12/26/2012OpGen Announces Sequence Assembly and Finishing of First Reference Genome of Domestic Goat - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
OpGen Contacts: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comDan Budwick (Media) Pure Communications, Inc. (973) 271-6085 Whole Genome Mapping Technology Plays Integral Role in International StudyGaithersburg, Md.—December 26, 2012— OpGen, Inc. today announced its ARGUS® Whole Genome Mapping System technology was used in combination with next-generation sequencing (NGS) to produce the first, high-quality reference genome of the domestic goat. The study, which w... 
Download PDFPrinter Friendly Version
12/19/2012OpGen Announces Partnership with University of California, Davis, to Develop High Resolution Microbial Genetic Maps in Support of The 100K Genome Project
OpGen Contacts: Michael Farmer Director, Marketing (240) 813-1284 office mfarmer@opgen.comDan Budwick (Media) Pure Communications, Inc. (973) 271-6085 UC Davis Contacts: Patricia Bailey Science/Agriculture writer UC Davis News Service (530) 752-9843 office (530) 219-9640 cell pjbailey@ucdavis.eduDr. Bart Weimer Professor, School of Veterinary Medicine Director, The 100K Genome Project (530) 754-0109 bcweimer@ucdavis.edu Whole Genome Maps to Aid in Outbreak Management and Surveil... 
Download PDFPrinter Friendly Version
11/19/2012OpGen Announces Expanded Adoption of Argus® Whole Genome Mapping System
Media Contact: Dan Budwick C. Pure Communications, Inc. (973) 271-6085OpGen Contact: Eric Winzer CFO OpGen, Inc. (240) 813-1273Major Genomics Sequencing Centers Worldwide Utilizing OpGen’s Whole Genome Mapping Technology Gaithersburg, Md.—November 19, 2012— OpGen, Inc., a commercial stage DNA analysis company, today announced the Argus® Whole Genome Mapping System continues to gain broad adoption among genome sequencing centers worldwide. Five leading international genomic sequencing c... 
Download PDFPrinter Friendly Version
05/30/2012Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279Companies to develop improved microbial analysis and surveillance systems for public health and infectious disease marketsCARLSBAD, Calif. and GAITHERSBURG, Md. – May 30, 2012 – Life Technologies Corporation (NASDAQ: LIFE) and OpGen, Inc., a commercial stage whole genome analysis company, today announced that they have signed a collaboration agreemen... 
Download PDFPrinter Friendly Version
05/17/2012Public Health Consortium to Evaluate Whole Genome Mapping for Improved Genetic Analysis of Disease Outbreaks
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279OpGen Announces Formation of Public Health Consortium to Evaluate Whole Genome Mapping for Improved Genetic Analysis of Disease OutbreaksGaithersburg, Md.—May 17, 2012— OpGen, Inc., a commercial stage whole-genome analysis company, today announced the formation of a public health consortium to evaluate OpGen’s Whole Genome Mapping technology as an en... 
Download PDFPrinter Friendly Version
05/01/2012OpGen Announces Strategic Collaboration with IQT to Develop High-Throughput Genomic Assembly and Analysis System - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Opgen Contact: Judy Macemon VP Marketing, Opgen, Inc. (240) 813-1279 OpGen Announces Strategic Collaboration with IQT to Develop High-Throughput Genomic Assembly and Analysis SystemGaithersburg, Md.—May 1, 2012— OpGen, Inc., a commercial stage whole-genome analysis company, today announced a strategic collaboration with In-Q-Tel (IQT), the non-profit, strategic investment firm that delivers innovative technology s... 
Download PDFPrinter Friendly Version
03/07/2012OpGen Completes Growth Capital Financing
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279Proceeds to Support Continued Commercialization of Whole Genome Mapping Technology Gaithersburg, Md.—March 7, 2012— OpGen, Inc., a commercial stage whole-genome analysis company, announced today that it has reached agreement with new and existing investors to raise up to $17 million in a new growth capital financing. Harris & Harris Group, Inc. a... 
Download PDFPrinter Friendly Version
02/23/2012OpGen Announces Participation in New European Union Clinical Microbiology Research Consortium
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279Project to Combine Next Generation Sequencing with Whole Genome Mapping to Genotype and Diagnose MRSA, Tuberculosis and ampylobacter SpeciesGaithersburg, Md.—February 23, 2012— OpGen, Inc., a whole-genome analysis company developing and commercializing a complete suite of break-through products and services based on its proprietary Whole Genome Mapping tec... 
Download PDFPrinter Friendly Version
02/14/2012OpGen Demonstrates Whole Human Chromosome Mapping Capabilities at 2012 AGBT Meeting
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279Findings Reveal Ability to Detect Structural Variations in Human Genomes, Providing Researchers with a New Tool to Investigate the Causes of Genetic DiseasesGaithersburg, Md.—February 14, 2012— OpGen, Inc., a whole-genome analysis company developing and commercializing a complete suite of break-through products and services based on its proprietary Whole G... 
Download PDFPrinter Friendly Version
01/17/2012OpGen’s Whole Genome Mapping System and Genome-Builder™ Software Suite Featured at the International Plant & Animal Genome XX Conference
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 Gaithersburg, Md.—January 17, 2012— OpGen, Inc., a whole-genome analysis company developing and commercializing a complete suite of break-through products and services based on its proprietary Whole Genome Mapping technology, announced today that the company’s new Whole Genome Mapping and Genome Builder™ software was featured in a poster session at the... 
Download PDFPrinter Friendly Version
12/20/2011OpGen Strengthens Management Team to Accelerate Commercialization Strategy
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 Contact:Gaithersburg, Md.—December 20, 2011— OpGen, Inc., a whole-genome analysis company developing and commercializing a complete suite of break-through products and services based on its proprietary Whole Genome Mapping technology, announced today the appointment of Vadim Sapiro as chief information officer. In addition, the company announced the promo... 
Download PDFPrinter Friendly Version
10/13/2011OpGen Announces Launch of Genome-Builder, a Breakthrough Advance for Sequence Assembly and Structure Variation Analysis in Large Genomes
Supporting Data Presented at ASHG Annual Meeting Highlights New Argus Whole Genome Mapping Software Module and Faster, More Accurate Project Completion CapabilitiesMedia Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 ASHG Booth #1019Gaithersburg, Md.—October 13, 2011— OpGen, Inc. announced today the launch of Genome-Builder, a high performance software module that provides... 
Download PDFPrinter Friendly Version
10/11/2011OpGen’s Whole Genome Mapping Technology Provides Critical Genomic Information for Malaria Research
New Genetic Variation Discovered in Multi-drug Resistant Plasmodium falciparum Malaria StrainMedia Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279GAITHERSBURG, MD, October 11, 2011 – The Walter Reed Army Institute of Research (WRAIR) and OpGen, Inc. today announced publication of findings by the WRAIR that indicate a breakthrough in malaria research (Malaria Journal www.mala... 
Download PDFPrinter Friendly Version
08/18/2011Frost & Sullivan New Product Innovation Award Recognizes OpGen’s Argus® Whole Genome Mapping System
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.comOpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279GAITHERSBURG, Md.–(BUSINESS WIRE)–OpGen, Inc., a provider of innovative whole genome DNA analysis solutions, announced today the company was chosen to receive the Frost & Sullivan 2011 Best Practice Award for New Product Innovation. The annual Frost & Sullivan awards spotlight “best-in-class” companies based on excelle... 
Download PDFPrinter Friendly Version
06/13/2011Optical Mapping First to Definitively Determine Deadly E. coli Strains in German Outbreak Are From a Single Source and Related to Earlier Outbreaks - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Whole Genome Analysis Adds Crucial Information to Better Understand and Manage the Ongoing E. Coli Outbreak in GermanyMedia Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.comOpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279GAITHERSBURG, MD, June 13, 2011 — OpGen, Inc. today announced successful completion of whole genome maps of the German outbreak E. coli isolates, performed in cooperation with the University Hospital Münst... 
Download PDFPrinter Friendly Version
05/23/2011The University of Maryland Institute for Genome Sciences (IGS) and OpGen, Inc Announce Collaboration to Develop Microbial Sequence Database
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (858) 472-1474 ASM Booth #237Gaithersburg, Md.—May 23, 2011— Today, at the American Society for Microbiology (ASM) Annual Meeting researchers at The University of Maryland Institute for Genome Sciences (IGS) and OpGen, Inc., a whole genome DNA analysis company, announced that they will collaborate to develop a database of high quality, finished, annotated microbial seq... 
Download PDFPrinter Friendly Version
02/08/2011OpGen Announces Argus® Optical Mapping System Purchase by BGI
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085Gaithersburg, Md.—February 8, 2011—OpGen, Inc., a genomics and DNA analysis company and exclusive provider of optical mapping technology, today announced that BGI, the largest genomics organization in the world, purchased an Argus™ Optical Mapping System. BGI plans on incorporating the Argus system into its current sequencing platform for microbial genome sequence finishing and sequence validation.“We are very encouraged by th... 
Download PDFPrinter Friendly Version
01/06/2011OpGen Announces Argus® Optical Mapping System Purchase by Wellcome Trust Sanger Institute - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085Gaithersburg, Md.—January 6, 2011—OpGen, Inc. a commercial phase genomics and DNA analysis company, today announced that the Wellcome Trust Sanger Institute has purchased an Argus™ Optical Mapping System in order to reduce the time and cost of whole genome sequence assembly.The Mapping and Archive Sequencing Division at the Sanger Institute plans to begin Optical Mapping of bacteria and parasites in January 2011. “Traditional ... 
Download PDFPrinter Friendly Version
11/30/2010OpGen, Inc., to Present at the Piper Jaffray 22nd Annual Health Care Conference
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085OpGen, Inc., to Present at the Piper Jaffray 22nd Annual Health Care ConferenceGaithersburg, Md. – November 30, 2010 – OpGen, Inc. a commercial phase genomics company, today announced that Douglas White, chief executive officer, is scheduled to present at the Piper Jaffray 22nd Annual Health Care Conference on Wednesday, Dec. 1, 2010, at 1:30 p.m. in New York City.About OpGen, Inc. OpGen, Inc. is a leading innovator in the f... 
Download PDFPrinter Friendly Version
11/04/2010BGI and OpGen Collaborate on Use of Optical Mapping for Whole Genome Assembly - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085Gaithersburg, Md. – November 4, 2010 – BGI, the largest genomics organization in the world, and OpGen, Inc., a commercial phase genomics company and exclusive provider of Optical Mapping Technology, announced their joint effort to expand the use of Optical Mapping for de novo sequence finishing in human, plant and animal genomes.BGI and OpGen have successfully completed a study based on human genome data to close gaps in the e... 
Download PDFPrinter Friendly Version
09/27/2010OpGen Completes $17 Million Series B Financing
Names Evan Jones as Executive Chairman of the BoardMedia Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085Gaithersburg, Md. – September 27, 2010 – OpGen, Inc., a commercial phase genomics company, today announced the successful completion of a $17 million Series B equity financing. The new round of financing was led by jVen Capital with participation from the company’s other major investors, including CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical and Vers... 
Download PDFPrinter Friendly Version